Previous Article in Journal
Unclosing Clinical Criteria and the Role of Cytokines in the Pathogenesis of Persistent Post-COVID-19 Headaches: A Pilot Case-Control Study from Egypt
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
CTN
Volume 9
Issue 1
10.3390/ctn9010006
ctn-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Midterm Outcomes of Endovascular Treatment for Intracranial Atherosclerosis: High-Volume Versus Low-Volume Centres

by
Ahmed Abualhasan
1,2,
Guglielmo Pero
2,
Luca Quilici
2,
Mariangela Piano
2,
Luca Valvassori
2,
Khaled Sobh
3,
Ossama Mansour
4,
Ahmed Elbassiony
5,
Omar El-Serafy
1,
Edoardo Boccardi
2 and
Foad Abd-Allah
1,*
1
Department of Neurology, Faculty of Medicine, Cairo University, Cairo 11562, Egypt
2
Department of Neuroradiology, Ospedale Niguarda Ca’ Granda, 20162 Milan, Italy
3
Department of Neurology, Faculty of Medicine, Al-Azhar University, Cairo 11561, Egypt
4
Department of Neurology, Faculty of Medicine, Alexandria University, Alexandria 21544, Egypt
5
Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt
*
Author to whom correspondence should be addressed.
Clin. Transl. Neurosci. 2025, 9(1), 6; https://doi.org/10.3390/ctn9010006
Submission received: 14 November 2024 / Revised: 20 December 2024 / Accepted: 16 January 2025 / Published: 22 January 2025
(This article belongs to the Section Endovascular Neurointervention)
Browse Figures
Versions Notes

Abstract

:
Background: Intracranial stenting is still feasible, but its effectiveness is still investigational. Our study investigated outcomes of endovascular treatment in high-volume and low-volume centres. Methods: We retrospectively recruited 36 patients with intracranial atherosclerosis who underwent endovascular treatment from January 2014 to June 2016 at three low-volume centres (n = 18), and a single high-volume centre (n = 18). Detailed periprocedural records, as well as clinical and radiological follow-up data, were revised through at least one-year post-procedure. The outcome parameters included successful revascularization, occurrence of any death, stroke, and/or Transient Ischaemic Attack (TIA) after intervention or during the follow-up period, and restenosis (≥50%). Results: The successful revascularization rate was 97.2%. The 30-day rate of any death, stroke, and/or TIA was 13.9%. At a median clinical follow-up of 18 months, the rate of any death, stroke, and/or TIA was 27.8%. Rates of any death, stroke, and/or TIA at 30 days and 18 months were higher among patients treated in low-volume centres versus those treated in high-volume centres but without reaching statistical significance (22.2% versus 5.6%, p = 0.188; and 38.9% versus 16.7%, p = 0.137, respectively). Conclusions: Although not statistically significant, our study showed a higher incidence of death, stroke and/or TIA among patients treated in the low-volume centre compared to those treated in the high-volume centre.

1. Introduction

Intracranial Atherosclerotic Disease (ICAD) represents a devastating pathology with a high risk of recurrent cerebrovascular events, even with optimal medical therapy [1]. The SAMMPRIS and VISSIT trials were multicenter randomized controlled trials which compared the optimal medical therapy versus endovascular revascularization in ICAD patients [2,3]. Both trials concluded that the optimal medical therapy was better than the endovascular revascularization regarding safety and efficacy. However, both trials received a lot of criticism regarding their patient selection criteria and operators’ experience [4,5,6,7]. Seven-year data from the China Angioplasty and Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS) trial indicate that intracranial stenting offers no additional benefits for patients with intracranial stenosis [8]. This conclusion was reached despite using a refined methodology [6]. On the contrary, another trial conducted in a single centre in China, randomized patients with Middle Cerebral Artery (MCA) stenosis to either optimal medical therapy or endovascular revascularization [9]. They concluded that endovascular revascularization can be performed safely in carefully selected patients with MCA stenosis. Additionally, the results of the Wingspan stEnt system post-mArket surVEillance (WEAVE) trial showed an extremely low periprocedural adverse events rate (2.6%), suggesting that proper patient selection and operators’ experience may maximize the benefit from endovascular revascularization [10]. The recently published Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis (BASIS) trial demonstrated that combining balloon angioplasty with optimal medical management significantly reduced the risk of adverse events compared to optimal medical management alone [11]. These adverse events included any stroke or death within the first 30 days, as well as ischemic stroke or the need for revascularization of the qualifying artery between 30 days and 12 months post-treatment. In the current stroke guidelines, the usefulness of endovascular revascularization for ICAD patients is considered unknown and investigational [12,13,14].
Controversies usually arise regarding the relationship between clinical outcomes and the volume of specific surgical procedures or medical conditions treated in a given site. Few investigators have addressed this point for the endovascular treatment of ICAD [10,15,16]. The learning curve for mastering the safety precautions of intracranial stenting is crucial. High-volume sites may guarantee the success and safety of intracranial stenting and maintain the continuity of operators’ experience. Our study question was whether outcomes were similar among centres that treated high and low volumes of patients.

2. Materials and Methods

2.1. Study Population

We retrospectively recruited 36 patients with symptomatic severe ICAD who underwent attempted intracranial angioplasty and/or stenting from January 2014 to June 2016. Only patients who had a TIA or ischaemic stroke attributed to advanced intracranial atherosclerotic lesions (≥70% stenosis) were included. The analysis was performed by reviewing data in previously maintained databases at four centres with comprehensive neuroendovascular services. Clinical data were treated according to the local hospital rules. All clinical data analyzed were collected as part of routine diagnosis and treatment. We identified demographic, clinical, and radiological data, including vascular risk factors, qualifying events, other non-qualifying events, the National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), antithrombotic therapy at the time of the qualifying event, vascular imaging, and brain parenchymal imaging (CT or MRI).
The high-volume centre was defined in this study as a centre with an annual volume of ≥300 general neuroendovascular treatments per year, including at least ten endovascular treatments for intracranial atherosclerosis per year. Our study centres included one high-volume centre, which treated 26 patients with intracranial atherosclerosis over a period of 30 months, and three low-volume centres, which collectively treated 21 patients with intracranial atherosclerosis over the same period. Patients who underwent intracranial angioplasty and/or stenting as a rescue treatment in the setting of acute stroke treatment were excluded (n = 11). Thirty-six patients were grouped accordingly into two groups: patients treated in the high-volume centre (group HV, n = 18), and patients treated in the low-volume centres (group LV, n = 18).

2.2. Brain Parenchymal Imaging Analysis and the Most Likely Stroke Mechanisms

We defined the most likely mechanism of stroke related to ICAD according to infarct pattern on brain parenchymal imaging as follows: (1) artery-to-artery embolism for single or multiple scattered infarcts located in the territory supplied by a single intracranial artery either cortical, subcortical or both; (2) perforator occlusion for lacune-like lesions in the territory of perforating vessels that originate at the site of stenosis; (3) insitu thrombotic occlusion for infarctions that extensively involve the entire or most of the stenosed arterial territory; (4) hypoperfusion for borderzone infarcts occurring at the junction of two arterial territories, either cortical borderzone or internal borderzone; and (5) mixed mechanisms for multiple infarct patterns.

2.3. Angiographic Analysis

Digital subtraction angiography was reviewed for each patient to determine the exact degree of stenosis according to WASID trial standards [17]. Lesions were divided into three groups: 70–79%, 80–89%, and 90–99%. According to lesion length, lesions were divided into three groups: <5 mm, 5–10 mm, and >10 mm. Proximal vessels were considered tortuous if there were 2 or more acute curves that would be difficult to traverse.

2.4. Procedural Aspects

Detailed procedural aspects were obtained, including time from the qualifying event to the procedure, periprocedural antithrombotics, anesthesia, intraprocedural adverse events, pre-stent angioplasty, stent type, stent size, poststent angioplasty, use of intermediate catheters, wire exchange, no. of lesion pass (single or multiple), combined treatment of other lesions, residual stenosis, and post-procedural brain imaging.

2.5. Follow-Up Data

Follow-up data, including vascular adverse events, modified Rankin Scale (mRS), and vascular imaging, were revised at least one year after the procedure. The post-stenting antiplatelet regime was variable among our recruitment sites. The patient would continue dual antiplatelet (aspirin 100–150 mg plus clopidogrel 75 mg or aspirin 100–150 mg plus ticlopidine 500 mg) for 3–6 months, depending on follow-up vascular imaging, type of stent, and recurrent events. Patients would continue aspirin 100–150 mg for life. Patients with no follow-up at the outpatient service or by telephone contact were considered lost for follow-up.

2.6. Outcome Assessment

The outcome parameters included successful revascularization with residual stenosis <50%, occurrence of stroke, TIA and/or death after intervention or during the follow-up period, and restenosis (≥50%).

2.7. Statistical Analysis

Pre-coded data were entered on the computer using “Microsoft Office Excel Software” program (2016) for Windows. Data were coded and entered using the statistical package SPSS (Statistical Package for the Social Sciences) version 24. Data were summarized using mean, standard deviation, median, and range for quantitative variables, and as a frequency and percentage for categorical variables. Comparisons between quantitative variables were performed using the non-parametric Mann–Whitney test. For comparing categorical data, a Chi-square test was performed. The exact test was used instead when the expected frequency was less than 5. A p-value of less than 0.05 was considered statistically significant.

3. Results

3.1. Patient Characteristics

The age ranged from 37 to 81 years, with a median age of 63.5 years. There were 29 males (80.6%) and 7 females (19.4%). The most common risk factor among our study population was hypertension in 83.3% (30/36) of patients followed by: dyslipidaemia 66.7% (24/36), diabetes mellitus 33.3% (12/36), coronary artery disease 22.2% (8/36), hyperuricaemia 8.3% (3/36), obesity (BMI ≥ 30) 5.6% (2/36), peripheral vascular disease 5.6% (2/36), hyperhomocystienaemia 5.6% (2/36), and obstructive sleep apnea syndrome 5.6% (2/36). Smoking history among our study population was as follows: current 41.7% (15/36), former 8.3% (3/36), and never 50% (18/36). The qualifying event was stroke in 63.9% (23/36), and TIA in 36.1% (13/36). Twenty-three patients (63.9%) had suffered previous cerebrovascular events (stroke or TIA) other than the qualifying event. Twenty-nine patients (80.6%) were already receiving antithrombotic therapy at the time of the qualifying event; 14 patients (38.9%) on single antiplatelet, 12 patients (33.3%) on double antiplatelet, 2 patients (5.6%) on single antiplatelet plus anticoagulation, and 1 patient (2.8%) on anticoagulation alone. Qualifying event severity, measured by the National Institutes of Health Stroke Scale (NIHSS), was as follows: 14/36 (38.9%) mild with NIHSS <5, 15/36 (41.7%) moderate with NIHSS = 5–14, 7/36 (19.4%) severe with NIHSS = 15–24. Twenty-eight patients (77.8%) had preprocedural mRS ≤ 3. Eight patients (22.2%) had preprocedural mRS ˃ 3.
The symptomatic qualifying artery was basilar artery in 15 patients (41.7%), intracranial vertebral artery in 13 patients (36.1%), middle cerebral artery in 3 patients (8.3%), and intracranial internal carotid artery in 5 patients (13.9%). The time from the qualifying event to intervention ranged from 2 to 78 days, with a median time of 17 days. The most likely stroke mechanisms related to ICAD were mixed mechanisms in 47.2% (17/36), hypoperfusion in 27.8% (10/36), and artery-to-artery embolism in 25% (9/36). Neither perforator occlusion nor insitu thrombotic occlusion was present as the sole stroke mechanism in any patient of our study population. Thirteen patients (36.1%) had multiple significant ICAD (Figure 1). Five patients (13.9%) had concomitant significant Extracranial Atherosclerotic Disease (ECAD). Two patients (5.6%) had significant stenosis (≥70%) proximal to the target lesion, i.e., tandem stenosis. Twenty-one patients (58.3%) had tortuous proximal vessels (≥2 acute curves).

3.2. Procedure Characteristics

All procedures were performed under general anesthesia. Different endovascular treatment modalities were used. Primary balloon angioplasty without stenting was conducted in 3 patients (8.3%). The stents used were either balloon-expandable coronary or self-expanding neurovascular stents. Balloon-expandable coronary stents were used in 24 patients; 19 bare-metal (52.8%) and 5 drug-eluting (13.9%). Bare-metal coronary stents included: 15 PRO-Kinetic Energy® (BiotroniK AG, Bülach, Switzerland), and 4 Liberté® (Boston Scientific, Natick, MA, USA). Drug-eluting coronary stents included 2 Resolute Onyx® (Medtronic, Minneapolis, MN, USA), 2 Resolute Integrity® (Medtronic, Minneapolis, MN, USA), and 1 Xience Prime® (Abbott Vascular, Santa Clara, CA, USA). Self-expanding stents were used in 9 patients (25%). Self-expanding stents included 4 LVIS Jr® (MicroVention-Terumo, Tustin, CA, USA), 3 LEO Baby® (Balt, Montmorency, France), and 2 Wingspan® (Stryker, Kalamazoo, MI, USA). Pre-stent angioplasty was performed in 18 patients (50%). Six patients (16.7%) underwent complex revascularization procedures, including combined treatment of other significant lesions either to bypass severe tandem stenosis or to improve collateral circulation. Intermediate catheter was required in 3 patients (8.3%). Over-the-wire exchange was performed in 16 patients (44.4%). Regarding the number of lesion pass, it was a single pass in 30 patients (83.3%), and multiple passes in 6 patients (16.7%). Intraprocedural adverse events occurred during 2 procedures (5.6%), including distal embolization and branch occlusion.

3.3. Clinical and Radiological Follow-Up

Three patients (8.3%) were lost for follow-up. The median clinical follow-up time was 18 months. Follow-up vascular imaging was available for 30 patients (83.33%). The median radiological follow-up time was 12 months.

3.4. Outcome Parameters

Successful revascularization (Residual stenosis < 50%) was obtained in 97.2% (35/36). In one case with marked proximal vessel tortuosity, the self-expanding stent could not be advanced to stent a distal basilar artery stenosis. Neither a distal access catheter nor an intermediate catheter was available during this procedure due to insurance issues.
At 30 days, the rate of any death, stroke, and/or TIA was 13.9% (5/36), and the rate of any target territory related stroke and/or TIA was 11.1% (4/36). At a median clinical follow-up of 18 months, the rate of any death, stroke, and/or TIA was 27.8% (10/36). At 30 days, a fatal haemorrhagic stroke occurred in one patient, and fatal ischemic stroke occurred in two patients: all in the target territory. Two patients had a non-fatal ischaemic stroke at 30 days: one in the target territory and one in a territory other than the target territory. No TIAs or non-fatal haemorrhagic strokes occurred at 30 days. After 30 days, a fatal ischaemic stroke occurred in one patient, a non-fatal ischemic stroke occurred in two patients; all in the target territory, and three patients had TIAs; all in the target territory. A fatal haemorrhagic stroke after 30 days occurred in one patient as a complication of the antithrombotic therapy in a territory other than the target territory.
Restenosis (≥50%) at median radiological follow-up of 12 months was observed in 4 patients (11.1%): 2 patients were treated with self-expanding stents and 2 patients with bare-metal stents). All four patients had symptomatic restenosis. Two of these restenoses required endovascular re-treatment; 1 patient was re-treated with balloon angioplasty, and 1 patient with drug-eluting stent (Figure 2).

3.5. Comparison Between High and Low-Volume Centres

A comparison between patients treated in the high-volume centre (group HV, n = 18), and patients treated in low-volume centres (group LV, n = 18) regarding baseline and procedure characteristics was performed (Table 1).
There was no statistically significant difference between both groups regarding baseline patient and lesion characteristics. The median age was 65 years in group HV versus 61 years in group LV (p = 0.606). The median time from the qualifying event to the procedure was 14 days in group HV versus 21 days in group LV (p = 0.556). The most likely stroke mechanisms related to ICAD varied between both groups, but without reaching statistical significance (p = 0.124). Hypoperfusion was more frequently present in group HV versus group LV (38.9% and 16.7%, respectively). Conversely, artery-to-artery embolism was more frequently present in group LV versus group HV (38.9% and 11.1%, respectively). Mixed mechanisms were similarly present in both groups (50% for group HV and 44.4% for group LV).
Endovascular treatment modalities varied significantly between both groups (p < 0.001). Bare metal coronary stents were used as the sole treatment modality for patients treated in the high-volume centre. Conversely, modalities varied among patients treated in low-volume centres, including self-expanding stents (50%), drug-eluting coronary stents (27.8%), bare metal coronary stents (5.6%), and primary balloon angioplasty (16.7%). There was no statistically significant difference between both groups regarding clinical and radiological follow-up durations. The median clinical follow-up duration was 18.5 months for group HV and 17 months for group LV (p = 0.276). The median radiological follow-up duration was the same (12 months) in both groups (p = 0.790).
The incidence of outcome parameters showed no statistically significant difference between patients treated in the high-volume centre, and patients treated in low-volume centres. However, 30-day and 18-month rates of any death, stroke, and/or TIA were higher among patients treated in the low-volume centre versus those treated in the high-volume centre, but without reaching statistical significance (22.2% versus 5.6%, p = 0.188; and 38.9% versus 16.7%, p = 0.137, respectively). Similarly, 30-day and 18-month rates of target territory-related stroke and/or TIA were higher among patients treated in the low-volume centre versus those treated in the high-volume centre but without reaching statistical significance (16.7% versus 5.6%, p = 0.603; and 38.9% versus 16.7%, p = 0.137, respectively, Table 2).

4. Discussion

Our study question was whether outcomes were similar among centres that treated high and low volumes of patients. Our results showed that the incidence of intraprocedural adverse events, successful revascularization, and 30-day haemorrhagic stroke were not significantly different between both groups. However, the 30-day rate of any death, stroke, and/or TIA was higher among patients treated in low-volume centres versus those treated in the high-volume centre but without reaching statistical significance (22.2% versus 5.6%, p = 0.188). Similarly, the 18-month rate of any death, stroke, and/or TIA was higher among patients treated in low-volume centres versus those treated in the high-volume centre but without reaching statistical significance (38.9% versus 16.7%, p = 0.137). The 5.6% any death, stroke, and/or TIA rate at 30 days obtained among patients treated in our high-volume centre is similar to the 4.3% rate reported in a previous Chinese multicentre registry [18] and is lower than 30-day rates reported in the European INTRASTENT registry (12.4%) [19], and the endovascular arm of SAMMPRIS (14.7%) [2]. Similarly, at our high-volume centre, the rate of any death, stroke, and/or TIA at 18 months was 16.7%. This rate is lower compared to SAMMPRIS, which showed a 24.1% probability of any stroke or death at 24 months among endovascularly treated patients [20]. Also, it is considerably lower than the 36.2% any stroke or hard TIA rate at 12 months reported in the endovascular arm of VISSIT [3].
Few investigators studied the relationship between the outcome of intracranial stenting and the volume of patients treated in a given site. An analysis of the NIH Wingspan registry revealed that rates of all strokes and ischemic stroke in the target territory were significantly higher among patients treated in low enrolling sites (<10 patients) compared to high enrolling sites [15]. Similarly, analysis of the SAMMPRIS trial showed higher rates of hemorrhagic stroke in low enrolling sites (<12 patients) compared to high enrolling sites (9.8% versus 2.7%, p = 0.043) [16]. In the WEAVE trial, operators who had experience of >50 Wingspan cases before enrolment achieved a 0% periprocedural adverse events rate, while operators with <50 Wingspan cases before enrolment had a 4.8% periprocedural adverse events rate [10].
Although the 30-day death/ischemia rate did not reach statistical significance in our study, the observed 4-fold difference between low-volume and high-volume centres is clinically concerning. A potential explanation for the statistical insignificance of our results might be related to the small sample size. A small sample size might limit statistical power and prevent outcome differences from being statistically significant. The trend of more death, stroke, and TIAs among patients treated in the LV centre might be related to the type of stent, most likely stroke mechanism, and socioeconomic status variability among our recruitment sites. Half of the patients in the LV group were treated using self-expanding stents. Generally, using balloon-mounted stents or primary balloon angioplasty is technically simpler and demands less procedural time than “multistep” self-expanding stents, which require an over-wire catheter exchange with there being a risk of wire perforation and haemorrhagic complications [21,22]. Among patients treated in our low-volume centres, four patients had death and/or stroke within 30 days after intervention. Three of them were treated using self-expanding stents. The most likely stroke mechanisms could also influence the difference in the results between the two groups. In our HV centre, the main indication for the endovascular treatment of ICAD was hypoperfusion in the territory supplied by the target vessel, a condition more prone to respond to endovascular revascularization [23]. Conversely, artery-to-artery embolism was more frequently present in group LV. However, a recent subgroup analysis of the SAMMPRIS trial could not provide any evidence regarding the advantage of the endovascular treatment over the medical treatment in patients with hypoperfusion symptoms [24]. Some adverse events after endovascular revascularization might be attributed to the patient’s non-compliance to antiplatelet therapy, risk factors control, or even follow-up visits [25]. Socioeconomic status, as a robust determinant of healthcare outcomes, is varied between Egypt and Italy [26]. This variability might also influence the incidence of post-procedural adverse events among our study groups.
While the decision to proceed with intracranial stenting should come from recurrent events, despite aggressive medical therapy, this was not consistently implemented in our study. All patients were managed by vascular neurologists prior to their referral for endovascular treatment according to every local institutional protocol. The protocol varied among our recruitment sites. In some patients presenting with hemodynamic infarctions that might be related to a low flow situation based on a critical stenosis with insufficient collateral flow, endovascular treatment could relieve the patients’ symptoms dramatically. Those patients could not benefit from medical therapy, especially if this medical therapy requires lowering blood pressure. Additionally, a few patients were switched to oral anticoagulation after the failure of the dual antiplatelet before their referral for endovascular treatment.
Our study reported a restenosis rate of 11.1% at a median radiological follow-up of 12 months. The restenosis rate among HV group patients treated with bare-metal coronary stents as the sole treatment modality was 5.6% at a median radiological follow-up of 12 months. This rate is much less than the restenosis rates reported in the literature following balloon-mounted stent placement (10–20%) [27,28,29], and self-expanding stent placement (17.4–25%) [30,31]. Among the LV group patients treated with variable endovascular modalities, including 50% self-expanding stents, 27.8% drug-eluting coronary stents, and 16.7% primary balloon angioplasty, restenosis rate was higher (16.7%), but without reaching statistical significance (p = 0.603). This may add to the growing evidence that restenosis is seen less frequently with balloon-mounted stents [22,32].
Our study was not without limitations. The limitations of the current study should be considered when interpreting the results. The main limitation of our study is the small sample size. Our study was a retrospective cohort study with a non-randomized design. Another limitation is that our definition of high- and low-volume centres considers the global experience within each centre of treating intracranial atherosclerosis, and of neuroendovascular procedures in general. Patients were recruited from four different centres with ethnic, demographic, clinical, and procedural differences that may have introduced significant heterogeneity and influenced our study outcomes. Another significant limitation of our study is the lack of data on patient ethnicity and socioeconomic status (e.g., income level, education level, and insurance status). Variations in data collection and recording practises across centres may have influenced the observed differences in comorbidities prevalence. Lastly, our study recruited patients from a single high-volume centre. Our results may not be representative of all high-volume centres.

5. Conclusions

Our study showed a higher incidence of mortality and adverse events among ICAD patients treated in low-volume centres compared to those treated in high-volume centres without reaching statistical significance. Future prospective studies with larger sample sizes are warranted.

Author Contributions

All authors were engaged in the study’s design, manuscript review, manuscript editing, and final approval of the manuscript. All authors were involved in data acquisition and organization. A.A. and G.P. drafted the article. A.A. and F.A.-A. performed all the statistical analyses. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

In this retrospective cohort clinical study, analysis was performed by reviewing data in previously maintained databases. All clinical data analyzed were collected as part of routine diagnosis and treatment in respect of the local hospital rules. The policy of our hospitals does not require the ethics committee approval for retrospective clinical studies.

Informed Consent Statement

All patients signed the informed consent for the treatment and allowed anonymous use of their clinical and radiological data.

Data Availability Statement

Additional data and materials may be available on request. Requests should be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Chimowitz, M.I.; Lynn, M.J.; Howlett-Smith, H.; Stern, B.J.; Hertzberg, V.S.; Frankel, M.R.; Levine, S.R.; Chaturvedi, S.; Kasner, S.E.; Benesch, C.G.; et al. Comparison of Warfarin and aspirin for symptomatic intracranial arterial stenosis. N. Engl. J. Med. 2005, 352, 1305–1316. [Google Scholar] [CrossRef] [PubMed]
  2. Chimowitz, M.I.; Lynn, M.J.; Derdeyn, C.P.; Turan, T.N.; Fiorella, D.; Lane, B.F.; Janis, L.S.; Lutsep, H.L.; Barnwell, S.L.; Waters, M.F.; et al. Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis. N. Engl. J. Med. 2011, 365, 993–1003. [Google Scholar] [CrossRef] [PubMed]
  3. Zaidat, O.O.; Fitzsimmons, B.F.; Woodward, B.K.; Wang, Z.; Killer-Oberpfalzer, M.; Wakhloo, A.; Gupta, R.; Kirshner, H.; Megerian, J.T.; Lesko, J.; et al. Effect of a Balloon-Expandable Intracranial Stent vs. Medical Therapy on Risk of Stroke in Patients with Symptomatic Intracranial Stenosis. JAMA 2015, 313, 1240–1248. [Google Scholar] [CrossRef] [PubMed]
  4. Abou-Chebl, A.; Steinmetz, H. Critique of “Stenting Versus Aggressive Medical Therapy for Intracranial Arterial Stenosis” by Chimowitz et al in the New England Journal of Medicine. Stroke 2012, 43, 616–620. [Google Scholar] [CrossRef] [PubMed]
  5. Qureshi, A.I.; Al-Senani, F.M.; Husain, S.; Janjua, N.A.; Lanzino, G.; Lavados, P.M.; Nguyen, T.; Raymond, J.; Shah, Q.A.; Suarez, J.I.; et al. Intracranial Angioplasty and Stent Placement After Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial: Present State and Future Considerations. J. Neuroimaging 2012, 22, 1–13. [Google Scholar] [CrossRef]
  6. Gao, P.; Zhao, Z.; Wang, D.; Wu, J.; Cai, Y.; Li, T.; Wu, W.; Shi, H.; He, W.; Zhu, F.; et al. China Angioplasty and Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): A new, prospective, multicenter, randomized controlled trial in China. Interv. Neuroradiol. 2015, 21, 196–204. [Google Scholar] [CrossRef]
  7. Abualhasan, A.; Abd-Allah, F.; Pero, G.; Sobh, K.; Mansour, O.; El-Serafy, O.; Boccardi, E. Intracranial Stenting: Is It Still an Option for Treatment of Patients With Intracranial Atherosclerosis? Front. Neurol. 2019, 10, 1248. [Google Scholar] [CrossRef]
  8. Gao, P.; He, X.; Wang, H.; Wang, T.; Wang, D.; Shi, H.; Li, T.; Zhao, Z.; Cai, Y.; Wu, W.; et al. Stenting Plus Medical Therapy vs Medical Therapy Alone for Symptomatic Intracranial Artery Stenosis: Long-Term Results of a Multicentre, Randomised Controlled Trial. SSRN Preprint 2024. [Google Scholar] [CrossRef]
  9. Miao, Z.; Jiang, L.; Wu, H.; Bao, Y.; Jiao, L.; Li, S.; Wu, J.; Hua, Y.; Li, Y.; Zhu, J.; et al. Randomized Controlled Trial of Symptomatic Middle Cerebral Artery Stenosis. Stroke 2012, 43, 3284–3290. [Google Scholar] [CrossRef]
  10. Alexander, M.J.; Zauner, A.; Chaloupka, J.C.; Baxter, B.; Callison, R.C.; Gupta, R.; Song, S.S.; Yu, W.; Feng, L.; Bonovich, D.; et al. WEAVE Trial. Stroke 2019, 50, 889–894. [Google Scholar] [CrossRef]
  11. Sun, X.; Deng, Y.; Zhang, Y.; Yang, M.; Sun, D.; Nguyen, T.N.; Tong, X.; Peng, G.; Liu, A.; Xu, Y.; et al. Balloon Angioplasty vs Medical Management for Intracranial Artery Stenosis. JAMA 2024, 332, 1059–1069. [Google Scholar] [CrossRef] [PubMed]
  12. Psychogios, M.; Brehm, A.; López-Cancio, E.; De Marchis, G.M.; Meseguer, E.; Katsanos, A.H.; Kremer, C.; Sporns, P.; Zedde, M.; Kobayashi, A.; et al. European Stroke Organisation guidelines on treatment of patients with intracranial atherosclerotic disease. Eur. Stroke J. 2022, 7, XLII–LXXX. [Google Scholar] [CrossRef] [PubMed]
  13. Turan, T.N.; Zaidat, O.O.; Gronseth, G.S.; Chimowitz, M.I.; Culebras, A.; Furlan, A.J.; Goldstein, L.B.; Gonzalez, N.R.; Latorre, J.G.; Messé, S.R.; et al. Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory. Neurology 2022, 98, 486–498. [Google Scholar] [CrossRef]
  14. Kleindorfer, D.O.; Towfighi, A.; Chaturvedi, S.; Cockroft, K.M.; Gutierrez, J.; Lombardi-Hill, D.; Kamel, H.; Kernan, W.N.; Kittner, S.J.; Leira, E.C.; et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke 2021, 52, e364–e467. [Google Scholar] [CrossRef]
  15. Nahab, F.; Lynn, M.J.; Kasner, S.E.; Alexander, M.J.; Klucznik, R.; Zaidat, O.O.; Chaloupka, J.; Lutsep, H.; Barnwell, S.; Mawad, M.; et al. Risk factors associated with major cerebrovascular complications after intracranial stenting. Neurology 2009, 72, 2014–2019. [Google Scholar] [CrossRef]
  16. Derdeyn, C.P.; Fiorella, D.; Lynn, M.J.; Barnwell, S.L.; Zaidat, O.O.; Meyers, P.M.; Gobin, Y.P.; Dion, J.; Lane, B.F.; Turan, T.N.; et al. Impact of operator and site experience on outcomes after angioplasty and stenting in the SAMMPRIS trial. J. Neurointerv. Surg. 2012, 5, 528–533. [Google Scholar] [CrossRef]
  17. Samuels, O.B.; Joseph, G.J.; Lynn, M.J.; Smith, H.A.; Chimowitz, M.I. A Standardized Method for Measuring Intracranial Arterial Stenosis. AJNR Am. J. Neuroradiol. 2000, 21, 643–646. [Google Scholar]
  18. Miao, Z.; Zhang, Y.; Shuai, J.; Jiang, C.; Zhu, Q.; Chen, K.; Liu, L.; Li, B.; Shi, X.; Gao, L.; et al. Thirty-Day Outcome of a Multicenter Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China. Stroke 2015, 46, 2822–2829. [Google Scholar] [CrossRef]
  19. Kurre, W.; Berkefeld, J.; Brassel, F.; Brüning, R.; Eckert, B.; Kamek, S.; Klein, G.E.; Knauth, M.; Liebig, T.; Maskova, J.; et al. In-Hospital Complication Rates After Stent Treatment of 388 Symptomatic Intracranial Stenoses. Stroke 2010, 41, 494–498. [Google Scholar] [CrossRef]
  20. Derdeyn, C.P.; Chimowitz, M.I.; Lynn, M.J.; Fiorella, D.; Turan, T.N.; Janis, L.S.; Montgomery, J.; Nizam, A.; Lane, B.F.; Lutsep, H.L.; et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): The final results of a randomised trial. Lancet 2013, 383, 333–341. [Google Scholar] [CrossRef]
  21. Connors, J.J.; Wojak, J.C.; Hoppe, B.H. The Technique of Endovascular Intracranial Revascularization. Front. Neurol. 2014, 5, 246. [Google Scholar] [CrossRef] [PubMed]
  22. Piano, M.; Milonia, L.; Cervo, A.; Modello, B.; Macera, A.; Pero, G.; Quilici, L.; Boccardi, E.; Valvassori, L. Endovascular Treatment of Symptomatic Intracranial Vertebrobasilar Stenosis: A 10-Year Single Centre Experience Using Balloon-Expandable Coronary Artery Stents. J. Stroke Cerebrovasc. Dis. 2020, 30, 105431. [Google Scholar] [CrossRef] [PubMed]
  23. Alexander, M.J. Intracranial stenting for intracranial atherosclerotic disease: Still much to learn. J. Neurointerv. Surg. 2012, 4, 85–86. [Google Scholar] [CrossRef] [PubMed]
  24. Lutsep, H.L.; Lynn, M.J.; Cotsonis, G.A.; Derdeyn, C.P.; Turan, T.N.; Fiorella, D.; Janis, L.S.; Lane, B.F.; Montgomery, J.; Chimowitz, M.I. Does the Stenting Versus Aggressive Medical Therapy Trial Support Stenting for Subgroups With Intracranial Stenosis? Stroke 2015, 46, 3282–3284. [Google Scholar] [CrossRef] [PubMed]
  25. Roger, V.L.; Go, A.S.; Lloyd-Jones, D.M.; Adams, R.J.; Berry, J.D.; Brown, T.M.; Carnethon, M.R.; Dai, S.; De Simone, G.; Ford, E.S.; et al. Heart Disease and Stroke Statistics—2011 Update. Circulation 2010, 123, e18–e209. [Google Scholar] [CrossRef]
  26. The Lancet: Global Burden of Disease 2019. Available online: https://www.thelancet.com/infographics-do/gbd-2019 (accessed on 16 December 2024).
  27. Fiorella, D.; Chow, M.M.; Anderson, M.; Woo, H.; Rasmussen, P.A.; Masaryk, T.J. A 7-year experience with balloon-mounted coronary stents for the treatment of symptomatic vertebrobasilar intracranial atheromatous disease. Neurosurgery 2007, 61, 236–243. [Google Scholar] [CrossRef]
  28. Miao, Z.R.; Feng, L.; Li, S.; Zhu, F.; Ji, X.; Jiao, L.; Ling, F. Treatment of symptomatic middle cerebral artery stenosis with balloon-mounted stents: Long-term follow-up at a single center. Neurosurgery 2009, 64, 79–85. [Google Scholar] [CrossRef]
  29. Durst, C.R.; Geraghty, S.R.; Southerland, A.M.; Starke, R.M.; Rembold, K.; Malik, S.; Wintermark, M.; Liu, K.C.; Crowley, R.W.; Gaughen, J.; et al. Stenting of symptomatic intracranial stenosis using balloon mounted coronary stents: A single center experience. J. Neurointerv. Surg. 2014, 7, 245–249. [Google Scholar] [CrossRef]
  30. Zaidat, O.O.; Klucznik, R.; Alexander, M.J.; Chaloupka, J.; Lutsep, H.; Barnwell, S.; Mawad, M.; Lane, B.; Lynn, M.J.; Chimowitz, M. The NIH registry on use of the Wingspan stent for symptomatic 70–99% intracranial arterial stenosis. Neurology 2008, 70, 1518–1524. [Google Scholar] [CrossRef]
  31. Costalat, V.; Maldonado, I.L.; Vendrell, J.F.; Riquelme, C.; Machi, P.; Arteaga, C.; Turjman, F.; Desal, H.; Sedat, J.; Bonafé, A. Endovascular treatment of symptomatic intracranial stenosis with the Wingspan stent system and Gateway PTA balloon: A multicenter series of 60 patients with acute and midterm results. J. Neurosurg. 2011, 115, 686–693. [Google Scholar] [CrossRef]
  32. Yue, X.; Yin, Q.; Xi, G.; Zhu, W.; Xu, G.; Zhang, R.; Zhou, Z.; Ma, M.; Jin, G.; Liu, X. Comparison of BMSs with SES for Symptomatic Intracranial Disease of the Middle Cerebral Artery Stenosis. Cardiovasc. Intervent. Radiol. 2010, 34, 54–60. [Google Scholar] [CrossRef]
Ctn 09 00006 g001
Figure 1. A patient who suffered a right medial pontine infarction (arrow in (A)) and had several drop attacks due to a low flow situation based on a total occlusion of the left vertebral artery (arrow in (B)) and severe stenosis of the right vertebral artery at the vertebra-basilar junction (arrow in (C)). The aim of the treatment was to correct vertebrobasilar hypoperfusion. The decision was to revascularize the right vertebral artery and to leave the occluded left vertebral artery without intervention. An undersized coronary balloon-expandable stent was placed in the right vertebral artery at the site of the stenosis (arrows in (D,E)) with good resolution of the stenosis (F).
Figure 1. A patient who suffered a right medial pontine infarction (arrow in (A)) and had several drop attacks due to a low flow situation based on a total occlusion of the left vertebral artery (arrow in (B)) and severe stenosis of the right vertebral artery at the vertebra-basilar junction (arrow in (C)). The aim of the treatment was to correct vertebrobasilar hypoperfusion. The decision was to revascularize the right vertebral artery and to leave the occluded left vertebral artery without intervention. An undersized coronary balloon-expandable stent was placed in the right vertebral artery at the site of the stenosis (arrows in (D,E)) with good resolution of the stenosis (F).
Ctn 09 00006 g001
Ctn 09 00006 g002
Figure 2. A patient who suffered several drop attacks due to a stenosis of the right vertebral artery with concomitant occlusion of the left (A). The patient underwent endovascular treatment with placement of a coronary balloon-expandable stent, which resolved the stenosis and relieved the symptoms (B). Six months later, symptoms relapsed, and an in-stent restenosis was diagnosed (C). An everolimus-eluting coronary balloon-expandable stent was placed, covering the bare metal previously placed (D,E) with complete resolution of the in-stent restenosis (F). The patient had no new symptoms in the follow-up, with persistence of the patency of the treated artery.
Figure 2. A patient who suffered several drop attacks due to a stenosis of the right vertebral artery with concomitant occlusion of the left (A). The patient underwent endovascular treatment with placement of a coronary balloon-expandable stent, which resolved the stenosis and relieved the symptoms (B). Six months later, symptoms relapsed, and an in-stent restenosis was diagnosed (C). An everolimus-eluting coronary balloon-expandable stent was placed, covering the bare metal previously placed (D,E) with complete resolution of the in-stent restenosis (F). The patient had no new symptoms in the follow-up, with persistence of the patency of the treated artery.
Ctn 09 00006 g002
Table 1. Comparison between patients treated in the low-volume centres (LV group), and patients treated in the high-volume centre (HV group) regarding patient and procedure characteristics.
Table 1. Comparison between patients treated in the low-volume centres (LV group), and patients treated in the high-volume centre (HV group) regarding patient and procedure characteristics.
CharacteristicLV Group
(n = 18)		HV Group
(n = 18)		p Value
No. (%)No. (%)
Male sex14 (77.8)15 (83.3)1
Hypertension15 (83.3)15 (83.3)1
Diabetes mellitus8 (44.4)4 (22.2)0.157
Coronary artery disease4 (22.2)4 (22.2)1
Dyslipidaemia13 (72.2)11 (61.1)0.480
Smoking historyNever7 (38.9)11 (61.1)0.357
Former1 (5.6)2 (11.1)
Current10 (55.6)5 (27.8)
Peripheral vascular disease02 (11.1)0.486
Obesity02 (11.1)0.486
Hyperuricaemia03 (16.7)0.229
Hyperhomocystienaemia02 (11.1)0.486
Obstructive Sleep Apnea Syndrome0 2 (11.1)0.486
Qualifying eventTIA5 (27.8)8 (44.4)0.298
Stroke13 (72.2)10 (55.6)
Previous non-qualifying cerebrovascular events10 (55.6)13 (72.2)0.298
stroke severity (NIHSS)mild (<5)5 (27.8)9 (50)0.101
moderate (5–14)7 (38.9)8 (44.4)
severe (15–24)6 (33.3)1 (5.6)
Preprocedural Functional statusmRs ≤ 314 (77.8)14 (77.8)1
mRs ˃ 34 (22.2)4 (22.2)
Symptomatic qualifying arteryBasilar8 (44.4)7 (38.9)0.167
Intracranial Vertebral4 (22.2)9 (50)
MCA3 (16.7)0
Intracranial ICA3 (16.7)2 (11.1)
Most likely stroke mechanismArtery-to-artery embolism7 (38.9)2 (11.1)0.124
Hypoperfusion3 (16.7)7 (38.9)
Mixed8 (44.4)9 (50.0)
Degree of stenosis (%)70–79%5 (27.8)3 (16.7)0.830
80–89%6 (33.3)7 (38.9)
90–99%7 (38.9)8 (44.4)
Lesion Length (mm)<5 mm3 (16.7)3 (16.7)1
5–10 mm12 (66.7)13 (72.2)
>10 mm3 (16.7)2 (11.1)
Concomitant significant large artery disease > 70%Multiple ICAD5 (27.8)8 (44.4)0.298
Concomitant Extracranial stenosis3 (16.7)2 (11.1)1
Concomitant significant tandem stenosis > 70%2 (11.1)00.486
Endovascular treatment modalityPrimary balloon angioplasty3 (16.7)0<0.001
Bare metal stent1 (5.6)18 (100)
Drug-eluting stent5 (27.8)0
Self-expanding stent9 (50)0
Pre-stent angioplasty12 (66.7)6 (33.3)0.0455
Combined Treatment of other lesions5 (27.8)1 (5.6)0.177
Tortous Proximal Vessels (≥2 acute curve)10 (55.6)11 (61.1)0.735
Intermediate catheter use1 (5.6)2 (11.1)1
Over wire exchange9 (50)7 (38.9)0.502
No. of lesion passSingle14 (77.8)16 (88.9)0.658
Multiple4 (22.2)2 (11.1)
Intraprocedural adverse events1 (5.6)1 (5.6)1
TIA: Transient Ischaemic Attack; NIHSS: National Institutes of Health Stroke Scale; MCA: Middle Cerebral Artery; ICA: Internal Carotid Artery; ICAD: Intracranial Atherosclerotic Disease.
Table 2. Comparison between patients treated in the low-volume centre (LV group), and patients treated in the high-volume centre (HV group) regarding incidence of outcome parameters.
Table 2. Comparison between patients treated in the low-volume centre (LV group), and patients treated in the high-volume centre (HV group) regarding incidence of outcome parameters.
Outcome ParameterLV Group
(n = 18)		HV Group
(n = 18)		p Value
No. (%)No. (%)
Successful revascularization (residual stenosis < 50%)17 (94.4)18 (100.0)1
Death, stroke, and/or TIA at 30 days4 (22.2)1 (5.6)0.188
Target territory-related stroke and/or TIA at 30 days3 (16.7)1 (5.6)0.603
Haemorrhagic stroke at 30 days1 (5.6)01
Death, stroke, and/or TIA after 30 days4 (22.2)3 (16.7)1
Target territory-related stroke and/or TIA after 30 days4 (22.2)2 (11.1)0.658
Death, stroke, and/or TIA at 18 months7 (38.9)3 (16.7)0.137
Target territory-related stroke and/or TIA at 18 months7 (38.9)3 (16.7)0.137
Restenosis (≥50%) at 12 month3 (16.7)1 (5.6)0.603
TIA, Transient ischaemic attack.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Abualhasan, A.; Pero, G.; Quilici, L.; Piano, M.; Valvassori, L.; Sobh, K.; Mansour, O.; Elbassiony, A.; El-Serafy, O.; Boccardi, E.; et al. Midterm Outcomes of Endovascular Treatment for Intracranial Atherosclerosis: High-Volume Versus Low-Volume Centres. Clin. Transl. Neurosci. 2025, 9, 6. https://doi.org/10.3390/ctn9010006

AMA Style

Abualhasan A, Pero G, Quilici L, Piano M, Valvassori L, Sobh K, Mansour O, Elbassiony A, El-Serafy O, Boccardi E, et al. Midterm Outcomes of Endovascular Treatment for Intracranial Atherosclerosis: High-Volume Versus Low-Volume Centres. Clinical and Translational Neuroscience. 2025; 9(1):6. https://doi.org/10.3390/ctn9010006

Chicago/Turabian Style

Abualhasan, Ahmed, Guglielmo Pero, Luca Quilici, Mariangela Piano, Luca Valvassori, Khaled Sobh, Ossama Mansour, Ahmed Elbassiony, Omar El-Serafy, Edoardo Boccardi, and et al. 2025. "Midterm Outcomes of Endovascular Treatment for Intracranial Atherosclerosis: High-Volume Versus Low-Volume Centres" Clinical and Translational Neuroscience 9, no. 1: 6. https://doi.org/10.3390/ctn9010006

APA Style

Abualhasan, A., Pero, G., Quilici, L., Piano, M., Valvassori, L., Sobh, K., Mansour, O., Elbassiony, A., El-Serafy, O., Boccardi, E., & Abd-Allah, F. (2025). Midterm Outcomes of Endovascular Treatment for Intracranial Atherosclerosis: High-Volume Versus Low-Volume Centres. Clinical and Translational Neuroscience, 9(1), 6. https://doi.org/10.3390/ctn9010006

Article Metrics

Back to TopTop